SCHEMBL110066

SCHEMBL110066

COC(=O)[C@@H](N)CSC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2692924 1.00
SCHEMBL16471260 1.00
Hydrochloric Acid SCHEMBL203270 0.98 KIF11 (0.42)
Hydrochloric Acid SCHEMBL2132352 0.98 KIF11 (0.42)
Hydrochloric Acid SCHEMBL203271 0.98 KIF11 (0.42)
SCHEMBL111172 0.86 KIF11 (0.43)
SCHEMBL111173 0.86 KIF11 (0.43)
SCHEMBL12438515 0.86 KIF11 (0.43)
SCHEMBL12438525 0.86 KIF11 (0.43)
SCHEMBL111171 0.86 KIF11 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424499-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER Abbott Laboratories (US) 2012-03-07 EP claimed
WO-2010127193-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBOTT LABORATORIES (US) 2010-11-04 WO claimed
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBVIE INC. 2010-11-04 US claimed
US-20240209255-A1 QUANTUM DOT MATERIAL, QUANTUM DOT LIGHT-EMITTING DEVICE AND PREPARATION METHOD THEREOF Beijing Boe Technology Development Co., Ltd. (CN) 2024-06-27 US disclosed
CN-117903239-A Method for realizing deuteration methylation of cysteine-containing polypeptide based on micro-flow field reaction technology 南京工业大学 2024-04-19 CN disclosed
US-11802107-B2 Compounds and methods of use SIGNUM BIOSCIENCES, INC. (US) 2023-10-31 US disclosed
CN-116745283-A Heterocyclic derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2023-09-12 CN disclosed
US-20230174467-A1 COMPOUNDS AND METHODS OF USE SIGNUM BIOSCIENCES, INC. (US) 2023-06-08 US disclosed
US-11518738-B2 Compounds and methods of use SIGNUM BIOSCIENCES, INC. (US) 2022-12-06 US disclosed
CN-110475474-B Compounds and methods of use 西格纳姆生物科学公司 2022-11-04 CN disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed
US-5034376-A Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1991-07-23 US disclosed
US-4935405-A Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1990-06-19 US disclosed
US-4931471-A Amides of paramethoxycinnamic and utilization thereof as solar filters UNIVERSITE LOUIS PASTEUR (FR) 1990-06-05 US disclosed
US-4814342-A Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1989-03-21 US disclosed
EP-0266950-A2 Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1988-05-11 EP disclosed
US-4523012-A INTERMEDIATES FOR PRODUCTION OF D,L-CYSTEINE AND DERIVATIVES DEGUSSA AKTIENGESELLSCHAFT (DE) 1985-06-11 US disclosed
EP-0051682-B1 CYSTEINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MITSUBISHI KASEI CORPORATION (JP) 1984-09-05 EP disclosed
US-4440788-A REGENERATION OF LIVER CELLS MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) 1984-04-03 US disclosed
EP-0051682-A1 CYSTEINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MITSUBISHI KASEI CORPORATION (JP) 1982-05-19 EP disclosed